Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma
NCT06893783Phase 2
Key facts
- Status
- Recruiting
- Start
- Sep 2025
- Primary completion
- Apr 2029
- Countries
- 1
- Modality
- Bispecific Antibodies, T-cell Engagers
- Drugs
- tarlatamab
- Conditions
- extrapulmonary neuroendocrine carcinoma (EPNEC)
01
Overview
Phase 2, open-label, single-arm trial of tarlatamab in extrapulmonary neuroendocrine carcinoma (EPNEC). Primary endpoint: Objective Response Rate at 36 months. Started Sep 2025; status: recruiting.
02
Design
1 arm- Study design
- Non-randomizedOpen-labelSingle group
All patient
Tarlatamab monotherapy for extrapulmonary neuroendocrine carcinoma
03
Who it enrols
Adults >=19 years with relapsed/refractory extrapulmonary neuroendocrine carcinoma (GI, pancreaticobiliary, or genitourinary) who progressed after 1 prior platinum-based regimen, with measurable disease, ECOG PS 0-2, and adequate organ function.
04
Endpoints
Primary
Objective Response Rate
Secondary
Progression-Free Survival
Overall Survival
Duration of Response
Beyond the preview
Go deeper on NCT06893783.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06893783.